Balance Sheet
Accounts PayablesAccumulated DepreciationAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulse Biosciences (PLSE) Accounts Payables (2020 - 2025)

Pulse Biosciences (PLSE) has 6 years of Accounts Payables data on record, last reported at $2.8 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 65.99% year-over-year to $2.8 million; the TTM value through Dec 2025 reached $2.8 million, up 65.99%, while the annual FY2025 figure was $2.8 million, 65.99% up from the prior year.
  • Accounts Payables reached $2.8 million in Q4 2025 per PLSE's latest filing, down from $3.0 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $3.5 million in Q1 2022 and bottomed at $1.4 million in Q3 2023.
  • Average Accounts Payables over 5 years is $2.2 million, with a median of $2.0 million recorded in 2022.
  • Peak YoY movement for Accounts Payables: surged 89.59% in 2021, then crashed 38.04% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $1.8 million in 2021, then dropped by 14.32% to $1.6 million in 2022, then rose by 16.72% to $1.8 million in 2023, then decreased by 8.88% to $1.7 million in 2024, then skyrocketed by 65.99% to $2.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $2.8 million in Q4 2025, $3.0 million in Q3 2025, and $2.7 million in Q2 2025.